QLT May Divest Products Or Place Entire Company Up For Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
“There isn’t anything we wouldn’t consider” parting with, QLT CEO tells “The Pink Sheet” DAILY; marketed products include wet AMD treatment Visudyne.
You may also be interested in...
QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.